- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Patent licensing swap ends MoAb fight
Monoclonal antibody competitorsNeoRx and Immunomedics have decided they have better things todo with their time and money than spend it in court. The two companiesannounced this month that they have settled a patent infringementbattle that began three
Monoclonal antibody competitorsNeoRx and Immunomedics have decided they have better things todo with their time and money than spend it in court. The two companiesannounced this month that they have settled a patent infringementbattle that began three years ago.
NeoRx of Seattle initiated the litigation in 1991 when it fileda lawsuit in U.S. District Court of New Jersey charging Immunomedicswith breach of contract and patent infringement of NeoRx patentson radionuclide labeling technologies (SCAN 4/20/94 and 9/11/91).Immunomedics, of Morris Plains, NJ, responded by filing a counterclaimagainst NeoRx.
In the settlement, the companies agreed to swap licenses topatents covering their respective technologies. Immunomedics willgive NeoRx a non-exclusive, royalty-free license to U.S. PatentNo. 4,331,647 for all of NeoRx's OncoTrac imaging agents. NeoRxwill give Immunomedics a non-exclusive, royalty-free license toU.S. Patent No. 4,877,868 for all of Immunomedics' imaging products.Neither company will receive or pay cash as part of the settlement.
Both companies are preparing for market launches of mono-clonalantibody-based imaging agents. NeoRx's OncoTrac kit for imagingsmall cell lung cancer is under review by the Food and Drug Administration.Immunomedics is steering its agent, ImmuRaid-CEA for imaging colorectalcancer, through the regulatory review process as well.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
